AI-powered Drug Discovery Startups

Tamarind provides a computational platform for protein and molecular engineering, offering AI and physics-based tools to design antibodies, peptides, enzymes, and small molecules. The platform integrates state-of-the-art published tools like AlphaFold and RFdiffusion through a user-friendly interface for life sciences companies.

2 investors

AtlasDiscovery develops foundation models of patient drug response trained on pre-clinical and clinical data to improve drug trial design and success rates. The company serves pharmaceutical and biotech firms by predicting human drug responses and enabling drug rescue and development in the biotech industry.

1 investor

Convexia provides AI-powered drug discovery and evaluation software that scans global sources for overlooked drug assets and runs deep in silico simulations across 50+ models to assess binding, toxicity, pharmacokinetics, and immunogenicity. The platform combines AI agents with expert human review to accelerate drug asset evaluation for biotech companies, pharma firms, and venture investors.

1 investor

Evolvere BioSciences develops antibiotics using computational models and evolutionary data to target pathogenic bacteria while preserving beneficial microbes, designed to resist the development of bacterial resistance.

1 investor

Keylika develops a platform synthesis technology for mixed ligand metal complexes to generate organometallic drugs for treating therapeutic conditions including hematology, pain, inflammation, metabolic disorders, infectious diseases, and oncology. The company combines drug development with drug delivery technologies, customizing molecular structure and formulation to optimize clinical outcomes for women, children, elderly, and patients with specific diseases.

1 investor

Known Medicine develops a predictive engine using AI and patient datasets to identify optimal cancer treatments for individual patients. The company serves oncologists and cancer patients through computational analysis of biomaterials and drug-discovery data.

1 investor

Macromoltek provides computational modeling and AI-driven antibody design services to biotech and pharmaceutical companies, accelerating the discovery and optimization of therapeutic antibodies. The platform reduces time-to-market and increases the probability of clinical success in drug development.

1 investor

Matrubials develops antimicrobial peptides derived from milk to create novel therapeutics for bacterial infections, starting with bacterial vaginosis. The company uses AI-enabled technology to identify and validate bioactive molecules for infectious disease treatments.

1 investor

Rasyn.ai offers Marigold, an AI research assistant that lets scientists ask research questions, run tools, or delegate entire tasks, returning results such as structures, charts, code, and papers in panels. It provides 54 runnable tools, 40 executing on connected hardware and 14 on hosted endpoints.

1 investor

Rosebud Biosciences develops therapies for rare genetic diseases in children by creating organoid models that replicate patient genetic mutations and using drug screening to identify potential cures. The company uses human-derived organoids combined with robotics and machine learning to accelerate drug discovery across cardiac, hepatic, neural, and kidney disease targets.

1 investor

Teevox makes an iOS remote control application that lets users control Hulu and Netflix playback, including episode selection, synchronized viewing with others, and standard media controls.

1 investor

WonderTx is an AI-native biotech that develops extrapolative AI models to discover oral drug molecules for targets with validated human biology that currently lack a viable pill-based treatment. The company aims to convert injectable therapies into pills and works on both its own and partner drug discovery programs.

1 investor